OCT 29, 2014 06:00 AM PDT
Expanding the scope of RNA-Seq to archival FFPE samples
Presented at the Cancer: Research, Discovery and Therapeutics Virtual Event
4 46 1407

Speakers:
  • Research & Development Scientist, Thermo Fisher Scientific
    Biography
         Dr. Bramlett leads the RNA Sequencing Applications Team at Life Sciences Solutions, Thermo Fisher Scientific. She guides the Research & Development effort focused on creating innovative sequencing and data analysis solutions for the detailed analysis of RNA. Prior to joining Thermo Fisher Scientific, Dr. Bramlett was a drug development scientist at Eli Lilly and Company, where she led a team of scientists specializing in gene regulation and nuclear receptor biology to identify novel drug targets. Dr. Bramlett built her background and experience in gene regulation through prior academic positions at Baylor College of Medicine and the M.D. Anderson Cancer Center. Kelli holds an undergraduate degree in Chemistry from Rice University in Houston, Texas, and a masters degree in Pharmacology from the Indiana University School of Medicine in Indianapolis, Indiana.

    Abstract:
    As next-generation sequencing (NGS) platforms advance in their speed, ease-of-use, and cost-effectiveness, many translational researchers are transitioning from microarrays to RNA sequencing (or RNA-seq) for their gene expression analysis needs. RNA-seq goes beyond differential gene expression to provide fundamental insights into how genomes are organized and regulated. New RNA-seq solutions now offer higher sensitivity, increased sample number flexibility, and the ability to analyze highly degraded or rare samples from as little as 10 ng of input RNA. Dr. Bramlett will discuss how NGS and RNA-seq can be applied for the discovery of new tumor biomarkers in archived formalin-fixed, paraffin-embedded (FFPE) samples.

    Show Resources
    Loading Comments...